Breakthrough Preclinical Data on DARPin-based Radiopharmaceuticals Highlight Potential for Advanced Cancer Therapies...
Published / Modified Jun 11 2024
CSIMarket Team / CSIMarket.com
Molecular Partners and Orano Med Report Promising Preclinical Data on Novel Radiopharmaceuticals
June 11, 2024 - Zurich-Schlieren, Switzerland, Concord, Mass. and Paris' - Molecular Partners(https://www.globenewswire.com/Tracker'data=OSD7vmGVEbVAsNMV8hJaq5rF979qq-i44SjCLAgsgvV9t9xM73YqViqymzpbaIwFvEzkoIpiKNXVZ77CNXKcEyI6yJB4QvupNxUtvSgC0b0=) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology company specializing in DARPin (Designed Ankyrin Repeat Proteins) therapeutics, along with Orano Med, a clinical-stage radiopharmaceutical entity focusing on targeted alpha therapies utilizing lead-212 (^212Pb), has announced encouraging preclinical data for their DLL3-targeting Radio-DARPin therapy (RDT) candidate, MP0712. The findings were disclosed during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting, held from June 8-11 in Toronto, Canada.
Focus on Small Cell Lung Cancer (SCLC) and DLL3+ Neuroendocrine Tumors
Molecular Partners and Orano Med showcased MP0712, their pioneering RDT candidate designed to target Delta-like protein 3 (DLL3). The presentation focused on how MP0712 harnesses the potent therapeutic payload of lead-212 (^212Pb), highlighting the significant progress towards its clinical evaluation in small cell lung cancer (SCLC) and other DLL3-positive neuroendocrine tumors.
The duo's collaborative efforts aim at deploying DLL3-targeting strategies due to DLL3?s specific overexpression in SCLC and other neuroendocrine tumor cells, making it an attractive target for radiopharmaceutical interventions. This approach could offer new therapeutic avenues for cancer types with limited treatment options, potentially improving patient outcomes.
Key Findings from Presentations
The preclinical data unveiled during the SNMMI conference included several key highlights:
- 'Enhanced Efficacy:' MP0712 demonstrated substantial therapeutic efficacy in preclinical models of DLL3-positive cancers.
- 'Target-Specific Action:' The data confirmed the high specificity of MP0712 for DLL3, thereby minimizing potential off-target effects.
- 'Potential in SCLC:' The promising results in small-cell lung cancer emphasize the potential of MP0712 to fill a significant gap in current treatment options for this aggressive cancer type.
Complementary Developments in DARPin Therapeutics
In a related advancement, Molecular Partners announced the publication of preclinical data for another of its DARPin-based candidates, MP0533, in the renowned journal 'Cancer Immunology Research' on April 29, 2024. This comprehensive publication details the proposed mechanism of action (MoA) for MP0533, a therapeutic aimed at treating acute myeloid leukemia (AML).
Mechanism of Action of MP0533
The publication highlights MP0533's distinct MoA, which has been supported by multiple preclinical studies aimed at characterizing its profile:
- 'Targeting Acute Myeloid Leukemia:' MP0533 is designed to engage immune cells, directing them to target and eliminate AML cells.
- 'Preclinical Validation:' The studies provide a robust validation of MP0533?s therapeutic potential, indicating its effectiveness against AML.
A Step Towards Innovative Cancer Therapies
The advancements showcased in the preclinical data from both MP0712 and MP0533 underscore the broader potential of DARPin-based therapeutics in oncology. By combining novel targeting mechanisms with potent therapeutic payloads, Molecular Partners aims to advance the treatment landscape for various hard-to-treat cancers.
Conclusion
These promising preclinical outcomes reflect significant strides in the development of novel therapeutic approaches for cancer, showcasing the potential of DARPin-based RDTs in offering targeted, effective treatments for challenging cancer types such as SCLC and AML. As the therapies progress towards clinical evaluation, they hold the promise of improved patient outcomes and expanded treatment options in oncology.
More Clinical Study News |
Clinical Study
Actuate Therapeutics Pioneers Pediatric Oncology Positive Phase 1 Results for Elraglusib in Ewing SarcomaJuly 17, 2025 |
Clinical Study
Eledon Pharmaceuticals Inc., a biopharmaceutical company focusing on therapeutics for kidney tr...July 17, 2025 |
Clinical Study
Navigating Challenges Capricor Therapeutics Advances Despite FDA Setback for Duchenne Muscular Dystrophy Therapy,July 11, 2025 |
Previous News
Trane Technologies: Fueling Growth and Delivering Returns for Investors
VICI Properties Inc. Maintains Dividend Amid Market Turbulence
Generative AI Ignites Broader Adoption of Analytical AI Among Businesses, Pegasystems Research Finds
TRTX Declares Cash Dividend for Series C Preferred Stock: Impact on Shareholders Explained
The Real Brokerage Inc. Makes Waves in the Stock Market by Joining Russell 3000 Index
Mobix Labs: Unleashing the Power of Advanced Connectivity Solutions
Previous News
Trane Technologies: Fueling Growth and Delivering Returns for Investors
VICI Properties Inc. Maintains Dividend Amid Market Turbulence
Generative AI Ignites Broader Adoption of Analytical AI Among Businesses, Pegasystems Research Finds
TRTX Declares Cash Dividend for Series C Preferred Stock: Impact on Shareholders Explained
The Real Brokerage Inc. Makes Waves in the Stock Market by Joining Russell 3000 Index
Mobix Labs: Unleashing the Power of Advanced Connectivity Solutions